Several other equities research analysts have also issued reports on the company. TheStreet lowered Seagen from a c- rating to a d+ rating in a research note on Friday, November 3rd. Truist Financial reaffirmed a hold rating and issued a $229.00 price objective on shares of Seagen in a research note on Wednesday, October 18th. Ten analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, Seagen currently has a consensus rating of Hold and a consensus target price of $197.69.
Seagen Price Performance
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Seagen by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 12,279,156 shares of the biotechnology company’s stock worth $1,768,813,000 after acquiring an additional 139,117 shares in the last quarter. BlackRock Inc. raised its position in shares of Seagen by 7.6% in the 2nd quarter. BlackRock Inc. now owns 12,041,819 shares of the biotechnology company’s stock worth $2,317,568,000 after acquiring an additional 850,697 shares in the last quarter. Primecap Management Co. CA raised its position in shares of Seagen by 3.7% in the 3rd quarter. Primecap Management Co. CA now owns 6,261,798 shares of the biotechnology company’s stock worth $1,328,440,000 after acquiring an additional 222,990 shares in the last quarter. State Street Corp raised its position in shares of Seagen by 0.7% in the 1st quarter. State Street Corp now owns 3,525,411 shares of the biotechnology company’s stock worth $507,835,000 after acquiring an additional 24,853 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Seagen in the 4th quarter worth $281,065,000. 84.26% of the stock is currently owned by hedge funds and other institutional investors.
Seagen Inc, a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer.
- Five stocks we like better than Seagen
- Health Care Stocks Explained: Why You Might Want to Invest
- 3 attractive stocks that insiders are buying
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Seagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seagen and related companies with MarketBeat.com's FREE daily email newsletter.